Markets

Alexion (ALXN) Misses on Q4 Earnings and Revenues

Alexion Pharmaceuticals, Inc.ALXN focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.

Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).

The company's track record has been mixed. Over the last four quarters, the company has beaten estimates on two occasions. Overall, Alexion has posted an average positive earnings surprise of 1.68% for the four trailing quarters.

Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Alexion missed on earnings expectations in the fourth quarter of 2016. Our consensus called for EPS of $1.10, and the company reported EPS of $1.07 (these figures include stock-based compensation expense).

Revenue: Revenues were also below expectations. Alexion posted revenues of $831 million, compared to our consensus estimate of $837 million.

Key Stats: Solirus sales declined 8.7% in the quarter to $749 million.

2017 Guidance: The company expects adjusted earnings per share to be in the range of $5.00 to $5.25. It projects revenues to be in the range of $3.4 to $3.5 billion. The Zacks Consensus Estimate for earnings was $4.80 per share while for sales it was $3.53 billion.

Alexion Pharmaceuticals, Inc. Price and EPS Surprise

Alexion Pharmaceuticals, Inc. Price and EPS Surprise | Alexion Pharmaceuticals, Inc. Quote

Just Released - Driverless Cars: Your Roadmap to Mega-Profits Today

In this latest Special Report, Zacks' Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making - autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ALXN

Other Topics

Earnings Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More